The groundbreaking medication, Mounjaro, is generating considerable anticipation within the diabetes community as a potential advancement for controlling Non-Insulin-Dependent Metabolic Disorder. Unlike some existing approaches, Mounjaro utilizes a dual mechanism , targeting both GLP-1 receptors